Effect of losartan on high sensitive C-reactive and uric acid of essential hypertensive patients with hyperuricemia

Objective To evaluate the influence and safety of losartan on high sensitive C-reactive protein(hs-CRP) and serum uric acid(UA) of essential high blood pressure(HBP) patients with hyperuricemia (HUA).Methods Eighty HBP patients complicated with HUA were enrolled and divided into the losartan group with losartan 50 mg/d(n =40) and the nifedipine group with nifedipine gastrointestinal therapeutic system (GITS) 30 mg/d (n =40) for 6 months continuously.The serum levels of hs-CRP,UA,hepatic and renal functions,creatine kinase(CK) and blood pressure were measured.Results Compared with before therapy,the systolic blood pressure(SBP),diastolic blood pressure (DBP) were lower in two groups after 6-month treatment and the differences were statistically significant(losartan group:SBP:(158.5 ± 13.2) mmHg vs.(136.7 ± 9.4) mmHg,t =3.50,P ＜ 0.01 ; DBP:(95.6 ± 8.4) mmHg vs.(83.3 ± 6.4) mmHg,t =3.49,P ＜ 0.01 ; nifedipine group:SBP:(157.7 ± 13.9) mmHg vs.(134.6 ± 8.2) mmHg,t =3.53,P ＜ 0.01 ; DBP:(96.1 ± 8.9) mmHg vs.(81.2±6.8) mmHg,t =3.56,P ＜0.01).The differences in terms of systolic and diastolic blood pressure were not significant at post-treatment between losartan and nifedipine group.The serum levels of hs-CRP and UA were significantly lower after 6-month treatment than before treatment in losartan group ((5.68 ± 1.53) mg/L vs.(3.52 ± 0.57) mg/L,t =3.82,P ＜ 0.01 ; (502 ± 45) μmol/L vs.(450 ± 38) μmol /L,t =3.48,P＜ 0.01),but there was no change in nifedipine group(hs-CRP:(5.61 ± 1.64) mg/L vs.(5.33 ± 1.48) mg/L,t =1.34,P ＞ 0.05 ; UA:(499 ± 43) μmol/L vs.(489 ± 42) μmol/L,t =0.68,P ＞ 0.05).There was no significant change regarding of liver and kidney functions and serum CK in losartan group before and after treatment.No adverse reaction occurred in the losartan group.Conclusion Losartan treatment can decrease serum hs-CRP and UA of HBP patients complicated with HUA,and there is no serious adverse reactions and good security during treatment. Key words: Losartan;  Essential hypertension;  Hyperuricemia;  High sensitive C-reactive protein; Uric acid